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Available online 12 September 2006SummaryThe European Society of Thoracic Surgeons (ESTS) organized a workshop dealing with lymph node staging in non-small cell lung cancer. The
objective of this workshop was to develop guidelines for definitions and the surgical procedures of intraoperative lymph node staging, and the
pathologic evaluation of resected lymph nodes in patients with non-small cell lung cancer (NSCLC). Relevant peer-reviewed publications on the
subjects, the experience of the participants, and the opinion of the ESTS members contributing on line, were used to reach a consensus.
Systematic nodal dissection is recommended in all cases to ensure complete resection. Lobe-specific systematic nodal dissection is acceptable for
peripheral squamous T1 tumors, if hilar and interlobar nodes are negative on frozen section studies; it implies removal of, at least, three hilar and
interlobar nodes and three mediastinal nodes from three stations in which the subcarinal is always included. Selected lymph node biopsies and
sampling are justified to prove nodal involvement when resection is not possible. Pathologic evaluation includes all lymph nodes resected
separately and those remaining in the lung specimen. Sections are done at the site of gross abnormalities. If macroscopic inspection does not
detect any abnormal site, 2-mm slices of the nodes in the longitudinal plane are recommended. Routine search for micrometastases or isolated
tumor cells in hematoxylin-eosin negative nodes would be desirable. Randomized controlled trials to evaluate adjuvant therapies for patients
with these conditions are recommended. The adherence to these guidelines will standardize the intraoperative lymph node staging and
pathologic evaluation, and improve pathologic staging, which will help decide on the best adjuvant therapy.
# 2006 Elsevier B.V. All rights reserved.
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Defining the stage of a malignant disease is key for
planning therapy, estimating prognosis and for comparison of
studies [1]. The extent of lymph node involvement in patients
with non-small cell lung cancer (NSCLC) is themost important§ The first ESTS Workshop was organized during the first ESTS Spring Meeting
March 2004 Zurich Switzerland and was presented at the second ESTS Spring
Meeting April 2005 Athens Greece.
* Corresponding author. Tel.: +41 1 2558802; fax: +41 1 2558805.
E-mail address: walter.weder@usz.ch (W. Weder).
1010-7940/$ — see front matter # 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejcts.2006.08.008prognostic factor and influences therapeutic strategies [2].
There are internationally accepted definitions for lymph
node staging in NSCLC, however, there are some unanswered
questions regarding extent, nomenclature definition, and
surgical procedure of intraoperative lymph node evaluation.
Furthermore, the quality of pathologic assessment is ill-
defined and may vary between observers [3].
The council of the European Society of Thoracic Surgeons
(ESTS) initiated a workshop which took place in Zurich on
25th March and 6th July 2004 in order to standardize
definitions, surgical procedures, and pathologic evaluation.
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from II to IV [4], these guidelines were open for discussion on
the society’s website for its members and the relevant replies
were integrated in the final document.
A second manuscript dealing with the preoperative
evaluation of intrathoracic lymph node status in patients
with NSCLC will be published in the near future as the result
of a second ESTS workshop.2. Anatomy and lymph drainage of the lungs
Three planes of lymphatic drainage from the lungs are of
clinical importance: anterior, mediastinal, and posterior
(intercostal) routes. Several studies have demonstrated a
great anatomical variability of the lymphatic system of the
lungs which might serve as possible explanation for the
somewhat unpredictable pattern of lymphatic metastases of
lung tumors [5].
From the surgical point of view it is important to note that
segmental and subpleural lymphatics may drain directly toFig. 1. Regional lymph node stations for lung cancer staging [2paratracheal or supraclavicular stations which is a possible
explanation for skip metastases to these lymph node stations
without involvement of intrapulmonary or hilar nodes [6]. In
a study of 179 patients undergoing bronchial lymphoscintin-
graphy during investigation for NSCLC [7], mediastinal skip
metastases identified in 25% of cases. In addition, crossover
lymphatic drainage across the midline was frequently found.
This provides an explanation for tumor spread to contral-
ateral mediastinal lymph nodes, and for routine investigation
of the contralateral mediastinum by mediastinoscopy or PET.
Of particular importance was the propensity for left lower
lobe tumors to drain to the right paratracheal lymph node
groups.3. Mapping of lymph nodes to the appropriate station
The need for precise evaluation of lymph node status was
identified in order to guide therapy, to estimate prognosis, to
compare results from different institutions, and to conduct
multi-institutional trials.] (with kind permission from Chest to reproduce Fig. 1).
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1978 report by Naruke et al. [8], when anatomical
definitions were first used. In 1983, the American Thoracic
Society produced a system in which the vague terms ‘hilar’
and ‘mediastinal’ were replaced with definitions of nodal
levels based on constant anatomical landmarks which
could be identified in the operating theatre [9]. In 1986, a
Revised International Staging System was produced by the
AJCC and UICC [1] in which the lymph node levels remained
unchanged but the components of the N2 group changed
and in which a N3 category was created. In 1997, the
latest revised International Staging System was released
[2] and a new pulmonary and mediastinal lymph node
map proposed [10] (Fig. 1). In this latest revision the
clinical staging system was based on CT landmarks making
identification of stations 2 and 4 more difficult during
surgery. Of importance was the inclusion of nodes along the
anterior surface of the main stem bronchus within the
pleural reflection line in station 4 (N2). Furthermore,
the nodes in the midline should be classified as N2 rather
than N3.4. What are the persisting obstacles to lymph node
mapping?
4.1. Anatomical allocation
The group identified five areas where difficulty exists in
the interpretation of the definitions. These were: (1) the
watershed between stations 2 and 4 in the paratracheal
region; (2) the transition zone between station 4 and 10 at
the tracheo-bronchial angle; (3) the border between station
7 in the subcarinal area and station nodes 10 on the medial
side of the main stem bronchi; (4) the lower border of
subcarinal station 7 and the beginning of paraesophageal
station 8; and (5) the lymphatic watershed in the superior
mediastinum which was proposed to be along the left
margin of the trachea. Apart from the landmark of the
take-off of the upper lobe bronchus from the main
bronchus as a boundary between station 4 and 10, it was
felt that the demarcation between these other stations was
either arbitrary or not identifiable at mediastinoscopy or
intraoperative staging. Most of these controversies are
relevant because they either change clinical and patholo-
gical stage (according to the current TNM staging) in
points 2, 3, and 5 above or may have prognostic implications
as in 1 and 4.
The limitations of present nodal charts will be addressed
in a new International Nodal Chart that will be included in
the next revision of the UICC Staging System to be enacted
in 2009.
4.2. Number of nodes (ratio) and number of stations
The importance of the number of investigated versus
involved nodes and lymph node stations has not been
addressed in the current staging systems. It is thought that
the number of lymph node stations involved by tumor and
their anatomical location are important prognostic factors
[11].5. Intraoperative lymph node assessment
5.1. General remarks
Although it is admitted that nodal staging of non-small
cell lung cancer should be as accurate as possible, the
extent of mediastinal lymph node assessment during surgery
is controversial and there is no consensus.
Different techniques are used, ranging from simple visual
inspection of the unopened mediastinum to an extended
bilateral lymph node dissection. Furthermore, different
terms are used to define these techniques.
There are data which clearly show that systematic
sampling or nodal dissection improves intraoperative staging
in contrast to selected lymph node sampling, especially in the
detection of multi-level N2 disease [12,13].
The rate of occult N2 disease will also depend on
the methods used for preoperative staging. Whether
extending the lymph node dissection influences survival or
recurrence rate of the disease remains to be determined
[12—15].
A removal of at least six lymph nodes (UICC) from hilar and
mediastinal stations is recommended to define nodal staging
accurately and to determine pN0 status [16].
There is evidence that multi-level andmulti-nodal disease
or extracapsular involvement has a poorer prognosis [17].
5.2. Recommended definitions to describe intraoperative
lymph node assessment
- Selected lymph node biopsyIn this procedure, one or multiple suspicious lymph
node(s) are biopsied. This is only justified to prove N1 or N2
disease in patients in whom resection is not possible
(exploratory thoracotomy).- Sampling
Sampling is the removal of one or more lymph nodes
guided by preoperative or intraoperative findings which are
thought to be representative. Systematic samplingmeans a
predetermined selection of the lymph node stations
specified by the surgeon.- Systematic nodal dissection
All the mediastinal tissue containing the lymph nodes is
dissected and removed systematically within anatomical
landmarks. For left-sided tumors, in order to get access to
the high and low paratracheal nodes, the division of the
ligamentum arteriosus can be added, resulting in the
mobilization of the aortic arch. It was recommended that
at least three mediastinal nodal stations (but always
subcarinal) should be excised as a minimum requirement.
The nodes are separately labeled and examined histolo-
gically. Beside the mediastinal nodes, the hilar and the
intrapulmonary lymph nodes are dissected as well [16].- Lobe-specific systematic node dissection
In this procedure, the mediastinal tissue containing
specific lymph node stations are excised, depending on the
lobar location of the primary tumor.- Extended lymph node dissection
In this procedure, bilateral mediastinal and cervical
lymph node dissection is performed through median
sternotomy and cervicotomy.
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For complete resection of non-small cell lung cancer, a
systematic nodal dissection is recommended in all cases
[18,19]. Ideally, this should be done as an en-bloc resection,
when possible of the upper mediastinal nodes on the right
side (stations 2R and 4R), the limits of which are as follows:
cranially, brachiocephalic trunk; medially, the ascending
aorta and origin of aortic arch; anteriorly, the superior vena
cava; posteriorly, the esophagus; and inferiorly, the pul-
monary artery. Any visible nodes in front of the superior vena
cava and/or posterior to the trachea should be removed
(stations 3a and 3p). We can recommend the en-bloc
resection of the lower mediastinum, including the fatty
tissue from the diaphragm to the subcarinal space (stations 7,
8, and 9). On the left side, removal of the subaortic (station
5), para-aortic (station 6) and inferior paratracheal (4 L)
lymph nodes is minimally required. For a complete nodal
dissection of the left upper mediastinum, division of the
ligamentum arteriosus allowing mobilization of the aortic
arch is recommended, with special care not to injure the left
recurrent laryngeal nerve.
It is important that the nodal stations are excised and put
in different vials with separate labeling. The highest removed
mediastinal node should be identified.
After pathological examination of the lymphadenectomy
specimen, the number of involved lymph nodes and of the
nodal stations, and the status of the nodal capsule should be
documented.
Modifications in specific clinical situations- For peripheral squamous T1, a more selective nodal
dissection depending on the lobar location of the primary
tumor (lobe-specific systematic nodal dissection) is
acceptable, based on the detailed analysis of lobe-specific
lymphatic drainage published by Naruke et al. [20] and
Ichinose et al. [21]. It has been shown that the probability
of unforeseen N2 disease is very low (<5%) in such patients
[22,23].
The Bronchogenic Carcinoma Cooperative Group of the
Spanish Society of Pneumology and Thoracic Surgery, based
on Naruke’s and Ichinose’s findings, recommended a
minimal dissection of at least three of the following
mediastinal nodal stations depending on the lobar location
of the primary tumor [24]. This implies dissection and
histological examination of hilar and interlobar nodes
which have to be tumor-free on frozen section analysis
and the following lobe-specific node dissection is
performed:
right upper and middle lobe: 2R, 4R and 7;
right lower lobe: 4R, 7, 8 and 9;
left upper lobe: 5, 6 and 7;
left lower lobe: 7, 8 and 9.
In total, the lymphadenectomy specimen should include
at least six nodes.After induction therapy, the same recommendation for-
lymph node assessment should be applied. However, lymph
node dissection in the upper mediastinum after induction
therapy (especially chemotherapy, radiotherapy after
previous mediastinoscopy) may be technically difficult [25].- High-risk patients.Intraoperative lymph node assessment can be mini-
mized in high-risk patients undergoing minimal invasive
video assisted wedge resections but if the patient can
tolerate a lobectomy, standard recommendation of lymph
node assessment should be followed [26].7. Histopathological evaluation of the removed lymph
nodes
7.1. Recommendations
Recommendations about the histopathological evaluation
of the lymph nodes were published in 2001 by the ‘Association
of Directors of Anatomic and Surgical Pathology’ [3].
However, in practice, there is no established consensus.
The analysis of the nodes depends on the center, on the
pathologist and it is often difficult to find a compromise
between theoretical demands and practical feasibility. Some
recommendations can be given to define quality criteria for
this evaluation:- As a first step, all resected intrapulmonary, hilar, and
mediastinal nodes should be examined macroscopically. In
the presence of gross tumor, one hematoxylin-eosin (HE)
stained section should be performed at the most macro-
scopically suspicious site to demonstrate the metastasis
and its possible extracapsular extension.- If the macroscopic evaluation does not show any suspicion
of metastasis, a single section of a node should be avoided.
The probability to detect a metastasis on center section is
related to the size of the lymph node, the size of the lesion,
and the location of the tumor within the node [27]. To avoid
this problem, it is recommended to perform several
sections of the nodes, 2-mm slices in the longitudinal
plane and to examine each block separately. Thin sections
of 2 mm may increase the workload of the pathologist but
increase the detection rate of metastases. Small nodes can
be sliced and embedded in one block if possible.- There are different methods to detect additional meta-
static deposits in lymph nodes like serial sectioning or
immunohistochemistry (IHC). IHC using a cocktail of
cytokeratins such as the anti-epithelial antibody mAb
Ber-Ep4, AE1/AE3 is a sensitive and specific method for
detecting isolated tumor cells or clusters of cells. Three
levels of section are enough for this analysis [28,29].
However, serial sectioning is relatively laborious and time-
consuming and is therefore not practical as a routine [30].- The report from the pathologist should describe the
number of lymph nodes removed and studied, the overall
number of metastatic lymph nodes in each station, and the
status of the lymph node capsule.7.2. Definition—micrometastasis
A micrometastasis can be detected by standard histo-
pathology (HE staining), by IHC or by polymerase-chain
reaction (PCR) (sensitive method).
A micrometastasis is defined as a lesion 2 mm in
diameter compared with a metastasis which is larger than
2 mm [31]. It is obvious that the distinction between
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criterion is arbitrary.
Another important point is the distinction between
micrometastasis and isolated tumor cells. Isolated tumor
cells are defined as single tumor cells or small cell clusters,
showing no stromal reaction and no proliferative potential.
Isolated tumor cells can be detected by IHC, PCR or by other
molecular methods, and their size 0.2 mm. Thus, histo-
pathologically, the two terms ‘micrometastasis’ and ‘isolated
tumor cells’ correspond to two different entities. However, in
the literature, there is a mixture of different terminologies
and the term micrometastasis is used for isolated cells,
clusters of cells or true micrometastases according to the
definition. Indeed, nearly all the published data are dealing
with isolated cells and not with micrometastasis [32,33].
The incidence of isolated tumor cells is about 20—30%.
This incidence was observed in several reports and also in
patients with early-stage of NSCLC [34,35].
The detection of isolated tumor cells in the lymph nodes
might have therapeutic implications, since several reports
showed that isolated tumor cells are a significant negative
prognostic factor in patients with NSCLC [36—38].
At the moment, the nodes with isolated tumor cells are
not upstaged to N1 or N2 but are labeled pN0 (i positive or
negative), or pN0 (mol positive or mol negative) if non-
morphologic methods or PCR or other molecular methods
have been used [39].
Isolated tumor cells may be observed at an early NSCLC
stage and seem to predict a shortened recurrence-free
interval and a shorter overall survival, indicating a biologi-
cally more aggressive tumor. As a consequence, it would be
desirable to routinely analyze all HE negative nodes with IHC
or other molecular methods. Whether the patients with
isolated tumor cells would benefit from adjuvant therapies
has to be evaluated in prospective trials.
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